altimmune stock: Company & Market Guide

Altimmune (stock)

altimmune stock refers to Altimmune, Inc. (NASDAQ: ALT), a U.S. clinical-stage biopharmaceutical company whose equity is traded on the NASDAQ. This article explains what investors and interested readers need to know about altimmune stock: the company profile, core R&D programs (including the lead candidate pemvidutide), recent regulatory or clinical milestones through January 23, 2026, trading and options-market behavior, ownership and disclosure practices, principal risks, and where to find official information.

This guide is neutral, fact-focused and intended for information only — it does not offer investment advice. Readers who trade equities can consider using regulated trading platforms; for crypto-related services or custody, Bitget Wallet is recommended where applicable. All market figures and events called out below cite public market reports and company investor communications as of the date called out in each section.

Company overview

Altimmune is a clinical-stage biopharmaceutical company focused on developing peptide- and protein-based therapeutics for metabolic and liver diseases and other indications. The company is headquartered in the United States and pursues a pipeline strategy centered on a small set of lead programs with the goal of advancing candidates through late-stage clinical trials and potential regulatory review. Altimmune emphasizes therapies for obesity-related disorders and liver diseases among its strategic focus areas.

The corporate purpose and pipeline details are maintained in the company's investor communications and public filings. For official program descriptions, readers should consult the Altimmune investor relations materials and recent SEC filings cited in the References section below.

History and corporate milestones

Altimmune's corporate history includes a progression from early research-stage efforts to a clinical-stage company with multiple human programs. Over the past several years the company has advanced its lead candidate through clinical development, announced financings to support trial activity, and reported clinical readouts that have periodically influenced market sentiment.

Major categories of milestones relevant to investors include:

• Advancement of lead clinical candidates into Phase 2/Phase 3 study stages.
• Regulatory interactions and designations related to specific programs.
• Financing transactions to fund R&D and operations.
• Public announcements that create discrete market events (trial readouts, regulatory decisions, partnership agreements).

Specific milestone dates and descriptions are available in Altimmune's public press releases and SEC filings (see References). Notable recent events that materially affected share trading are summarized in the "Recent regulatory and clinical developments" and "Notable market reactions and case studies" sections below.

Business operations and product pipeline

Altimmune operates mainly as a research and development company; it does not currently have a marketed commercial product generating meaningful recurring revenue. The company's valuation and investor interest largely derive from the progress and data readouts of clinical-stage candidates.

R&D focus areas and strategy:

• Metabolic disease and obesity therapeutics using peptide-based mechanisms.
• Liver disease indications, including metabolic associated steatohepatitis (MASH/NASH) and alcohol-related liver disease (ALD/AUD) where applicable.
• Additional therapeutic programs in early-stage development, or earlier discovery-stage assets.

Altimmune's commercial strategy, when applicable, generally centers on completing pivotal clinical development and either seeking regulatory approval or exploring partnerships for commercialization. The precise commercial pathway differs by program and will depend on regulatory designations and trial outcomes.

Pemvidutide (lead candidate)

Pemvidutide is Altimmune's lead clinical-stage program and is frequently cited as the primary driver of altimmune stock performance. Public disclosures characterize pemvidutide as a long-acting peptide therapeutic engineered to target metabolic disease pathways; corporate materials and news coverage have described it in the class of GLP-1/glucagon dual agonists. That mechanism aims to combine appetite/metabolic effects of GLP-1 receptor activity with additional metabolic modulation from glucagon receptor agonism.

Key clinical development points (public summary):

• Development stage: pemvidutide has advanced through Phase 1 and Phase 2 studies; further pivotal studies have been planned or initiated depending on prior data and regulatory interactions.
• Clinical readouts: the company has disclosed early efficacy and tolerability data in obesity and liver-disease cohorts in prior releases. Data points of interest to investors typically include weight-loss percentages, liver-enzyme changes, histological endpoints for MASH/NASH, and safety/tolerability profiles.
• Strategic significance: pemvidutide is widely reported as the largest single valuation driver for altimmune stock because positive, robust Phase 2/3 data or favorable regulatory interactions could materially change the company's commercial prospects and financing flexibility.

As with any clinical-stage therapy, the program's future value depends on randomized-controlled trial results, regulatory decisions, and competitive landscape developments. Recent coverage on January 23, 2026, highlighted a regulatory milestone tied to the company's MASH therapy program (see "Recent regulatory and clinical developments").

Stock listing and market identifiers

• Ticker symbol: ALT
• Exchange: NASDAQ (primary listing)

Market data for altimmune stock is widely available through financial news services, market-data providers, and the company's investor relations pages. Public quotes shown on many data platforms may be delayed (typically by 15 minutes) unless marked as real-time. For the official company-maintained quote and chart, the Altimmune investor relations pages and SEC filings are primary sources.

Trading data and historical performance

As of January 23, 2026, market reporting captured a material intraday move and elevated trading activity for altimmune stock. According to a market activity report on that date, altimmune stock had a reported trading volume of 4,365,951 shares, a high of $6.30, a low of $5.3413, and a last reported trade near $6.25 (an intraday change of +$0.87). These intraday metrics were included in the broader list of most-active Nasdaq and NYSE securities compiled by market reporters on January 23, 2026.

Key trading metrics and where to find them:

• Intraday price, daily high/low, volume: provided by market-data services and the company IR quote.
• 52-week range, market capitalization, float and shares outstanding: available on major market-data pages and in the company's quarterly and annual reports.
• Average daily volume and historical price charts: tracked by market-data services and useful for assessing liquidity and volatility.

Historical performance for altimmune stock has shown episodic volatility tied to clinical and regulatory newsflow. Biotech equities, particularly clinical-stage companies without commercial revenue, commonly experience larger percentage moves on single data points or announcements compared with mature, revenue-generating companies.

Recent regulatory and clinical developments affecting the stock

As of January 23, 2026, market coverage and company disclosures noted a regulatory development linked to Altimmune's MASH-related therapy program. Media coverage on that date reported that altimmune stock surged following news that the company had received a notable regulatory designation or positive interaction regarding its MASH therapy program. This regulatory update was reported alongside unusually high trading and options-market activity on the same date.

Public sources active on January 23, 2026 reporting these developments included market news services and industry trade outlets. Because regulatory pathways and designations materially affect clinical development strategy, these kinds of announcements often drive immediate sentiment and volume in altimmune stock.

Financials and corporate disclosures

Altimmune is a development-stage company and has historically reported limited or no product revenue while incurring R&D and SG&A expenses consistent with clinical programs. Key financial considerations for altimmune stock investors include:

• Revenue: historically minimal or absent for the company while programs remain in clinical stages.
• Cash position and burn rate: the company periodically reports its cash runway, with operating cash burn primarily funding clinical trials. Exact cash and runway figures are disclosed in the company's quarterly (10-Q) and annual (10-K) SEC filings.
• Profitability: Altimmune has historically reported net losses while investing in R&D; profitability would depend on future successful commercialization or partnering outcomes.

For the most recent audited and interim financial metrics, investors should consult Altimmune's SEC filings and the company's latest investor presentation. The investor relations section and the company's Form 10-Q/10-K filings are primary sources for up-to-date financial disclosures.

Ownership, analyst coverage and market sentiment

Ownership structure and sentiment cues for altimmune stock typically include a mix of institutional investors, insider holdings (management and board stock positions and option grants), and retail investors. Analyst coverage in the biotech sector can be limited for smaller clinical-stage names; when coverage exists, analysts often focus on clinical-data milestones and regulatory catalysts.

As of January 23, 2026, market commentary showed heightened retail attention and social-media discussion concurrent with high trading volume and a jump in the share price. Reports on social platforms and message boards contributed to intraday and short-term sentiment shifts.

Insider transactions

Insider transactions for altimmune stock — including company officers and directors buying or selling shares or receiving option grants — are disclosed in SEC filings (Forms 4, 3 and Schedules) and company proxy statements. Public filings record the timing and size of these transactions; readers interested in insider activity should consult the SEC filing database and the company's investor relations disclosures for the most recent information.

Retail and social media sentiment

Retail-trader platforms and social channels showed increased discussion of altimmune stock during the January 23, 2026 market moves. Messaging activity on retail networks and ticker-focused communities often correlates with spikes in volume and options activity for smaller-cap biotech names. While social sentiment can amplify short-term price moves, it is not a substitute for primary source documentation of clinical and regulatory events.

Options market and derivatives activity

On January 23, 2026, options-market reporting noted unusually high call-option volume on altimmune stock. MarketBeat and other options-alert services highlighted that traders purchased large call blocks, which contributed to increased open interest and elevated option-implied volatilities. Unusual call purchase activity around clinical or regulatory windows is common in biotech equities as traders attempt to position for binary outcomes from trial readouts or regulatory decisions.

Points to consider about options activity tied to altimmune stock:

• Large call-volume spikes can reflect speculative positioning or hedged strategies by institutional traders.
• Elevated open interest and skew in call vs put volumes can increase implied volatility and options prices.
• Options flows should be interpreted in the context of confirmed corporate events; reported flow alone does not confirm an outcome.

MarketBeat's instant-alert coverage on January 23, 2026, specifically called out heavy call buying interest on the stock in connection with that day's regulatory/clinical news and the concurrent price move.

Risks and investment considerations

altimmune stock carries several principal risk categories that are common to clinical-stage biotechnology companies. This section summarizes those risks objectively and factually; it is not investment advice.

Principal risk factors include:

• Clinical and regulatory risk: trial results can be binary; positive readouts may advance a program, while negative or inconclusive results may materially reduce program value.
• Competitive risk: the metabolic and liver-disease therapeutic areas are active with multiple competing approaches; market adoption and differentiation are uncertain.
• Financing and dilution risk: as a developing company, Altimmune may need to raise additional capital which could dilute existing shareholders.
• Volatility and liquidity risk: smaller-cap biotech equities often show high intraday and multiday volatility; trading volume can vary significantly around news events.
• Operational risk: R&D timelines, manufacturing, and operational execution can affect development timelines and costs.

Investors and readers should rely on primary-source disclosures for legal and financial decision-making and should consult licensed financial professionals for personalized investment advice.

Corporate governance and management

Altimmune publishes governance documents, board composition, and information about senior management in its investor relations materials and proxy statements. Governance practices typically include oversight by an independent board, audit and compensation committees, and public disclosure of executive compensation and director independence.

For current information on the CEO, CFO, board members and committee charters, refer to the company’s most recent proxy statement and investor-relations governance pages.

Investor relations and communications

Investors can obtain official and up-to-date information from the company's investor relations resources and filings. Typical IR resources include the corporate press release feed, investor presentations, SEC filings (10-Q, 10-K, 8-K), and the company-maintained stock quote and chart. Altimmune’s investor relations team provides contact details in the IR section for inquiries from analysts, shareholders and media.

When seeking official financial statements or legal disclosures, use SEC filings as the authoritative record. The company's investor-relations pages contain links and PDFs of presentations, press releases and historical filings.

Notable market reactions and case studies

Several events have moved altimmune stock materially in the past. Recent examples around January 23, 2026 include:

• Regulatory/Designation News (Jan 23, 2026): Media and industry reports indicated a regulatory breakthrough or a favorable interaction for the company's MASH therapy program, which correlated with a notable intraday price increase and elevated trading volume for altimmune stock.

• Elevated Options Flow (Jan 23, 2026): MarketBeat and options-alert publications reported unusually high call buying on altimmune stock on the same date, consistent with speculative positioning around the regulatory news and contributing to higher implied volatility in options markets.

• Retail-Driven Volume Spikes: Message-board and social-platform activity tracked alongside the share move indicated heightened retail interest; such episodes have historically amplified intraday volatility in the ticker.

Each of these cases illustrates how clinical/regulatory news, options flow and retail sentiment can converge to produce rapid price and volume changes in a clinical-stage biotech equity.

See also

• Overview of GLP-1 and dual-agonist therapeutics
• Metabolic associated steatohepatitis (MASH/NASH) clinical endpoints
• Biotech clinical development phases and regulatory pathways
• Basics of options markets and implied volatility

References

All references below are public sources cited for factual reporting in this article. No external hyperlinks are included in this article. For original documents and filings, consult the named sources directly.

• Altimmune investor relations — Investor Overview and Stock Quote pages (company IR)
• Stocktwits — News articles and symbol discussion around ALT
• MarketBeat — Instant alert on high call-option purchases for Altimmune (report dated January 23, 2026)
• StocksToTrade — Article on reported FDA/regulatory breakthrough for MASH therapy (January 23, 2026 coverage)
• Yahoo Finance — ALT stock quote and historical data
• CNBC — ALT stock quote page and market coverage
• Robinhood — ALT profile and market snapshot
• MarketWatch — ALT stock page and summary
• AP/market-most-active compilation — market activity list including Altimmune (reporting as of January 23, 2026)

Reporting date and data notes

• As of January 23, 2026, market reporting (AP market most-active compilation and industry news coverage) recorded altimmune stock trading volume of 4,365,951 shares, a daily high of $6.30, a daily low of $5.3413 and a last trade near $6.25 on that date.

• MarketBeat published an options-market alert on January 23, 2026, noting unusually high call-option purchases on altimmune stock concurrent with the regulatory/clinical news that day.

Readers should verify current market prices and company filings for updates after January 23, 2026.

How to follow altimmune stock and official updates

• For official corporate disclosures and financial reports, consult Altimmune’s investor relations materials and SEC filings (Form 10-Q, Form 10-K, and 8-K for current events).
• Market-data snapshots (price, 52-week range, market cap) are available from major financial-data providers and the company’s IR stock-quote page.
• For derivatives and options-flow alerts, options-data services and professional platforms report volume and open-interest changes; MarketBeat was one of the services that flagged notable call-volume activity on January 23, 2026.

If you plan to trade public equities, consider using regulated trading venues and professional brokerage services. For custody or wallet services related to digital assets, Bitget Wallet is a recommended option among institutional-friendly solutions. For execution and margin trading in listed equities, use licensed brokers that comply with your local regulations.

Additional practical notes for readers

• Biotech news is highly catalyst-driven. For altimmune stock, keep an eye on pemvidutide clinical milestones, regulatory-designation announcements, and company-funded trials that establish pivotal endpoints.
• Monitor SEC filings for financing activity; post-funding dilution is a common risk in clinical-stage companies.
• When interpreting options-flow reports, consider that large call purchases may be speculative and do not guarantee a positive clinical outcome.

Further exploration

To stay current with altimmune stock developments:

• Check the company’s press-release feed and investor presentations frequently around anticipated clinical readouts.
• Review the latest SEC filings for precise financial metrics, insider transactions and official disclosures.
• Track market-data pages for real-time price and volume (note possible delay disclaimers on public data feeds).

Explore Bitget resources if you wish to learn about custody, wallets and execution products that the Bitget platform offers for digital-asset needs; Bitget Wallet is available for non-custodial key management if you also maintain a crypto exposure alongside traditional equity investing.

If you want a condensed market snapshot or a one-page briefing of altimmune stock events as of January 23, 2026, reply to request an executive summary.